Blood pressure drug may shield hearts during breast cancer radiation

NCT ID NCT05607017

Completed Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested whether losartan, a common blood pressure medication, could prevent early heart damage caused by radiation therapy in breast cancer patients. Five women with left-sided breast cancer who were scheduled for radiation took losartan. Researchers used heart MRIs to measure changes in heart tissue. The goal was to see if losartan could reduce the risk of future heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Losartan
What this could lead to: If it works, this could point toward a way to prevent heart failure in breast cancer patients receiving radiation therapy.
What could go wrong: This is a very early, tiny trial with only 5 participants, so results may not be reliable or apply to others. It only looked at early heart changes, not actual heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm endomyocardial fibrosis Radiation Fibrosis Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER MYOCARDIAL FIBROSIS RADIATION INDUCED FIBROSIS

Contacts and locations

Locations

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.